The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

siRNA halts ccRCC tumor growth in phase I trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

In a phase I clinical trial led by UT Southwestern Medical Center, a short interfering RNA drug directed to tumor cells effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Investigational therapy shrinks drug-resistant NSCLC by activating NK cells, study finds

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging an attack from natural killer cells in an animal model, a study led by UT Southwestern Medical Center researchers shows. The findings, published in the Journal for ImmunoTherapy of Cancer, could lead to new types of immunotherapy that rely on this novel strategy.
Clinical Roundup

UTSW scientists link hematopoietic cell transplant deaths to beta-blocker use

Patients can die if they take certain previously prescribed beta-blockers during a hematopoietic cell transplant due to suppressed signals from nerves that promote bone marrow regeneration, according to scientists at the Children’s Medical Center Research Institute at UT Southwestern, published in Cancer Discovery, builds upon previous CRI research by analyzing retrospective patient data to correlate beta-blocker use with significantly worse patient outcomes.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account